The world’s first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer.
The expansion will enable the World Health Organisation, WHO, the United Nations Children's Fund, UNICEF, the United Nations High Commissioner for Refugees, UNHCR, and the United Nations World Food Programme, UN-WFP, to send additional emergency relief items
This is a landmark collaboration to accelerate the development, production and equitable distribution of vaccines, diagnostics, and therapeutics for COVID-19